DHEA Supplement Guide: Benefits, Dosing, Forms, and Side Effects

DHEA Supplement Guide: Benefits, Dosing, Forms, and Side Effects

Last Updated:

Dehydroepiandrosterone (DHEA) is a steroid hormone produced primarily by the adrenal glands, with smaller contributions from the gonads and brain [1][2]. It is the most abundant circulating steroid hormone in the human body and serves as a precursor to both androgens (including testosterone) and estrogens (including estradiol), after first being converted to androstenedione [1][2][3]. DHEA circulates predominantly in its sulfated form, DHEA sulfate (DHEA-S), which has a longer half-life and serves as a reservoir that tissues can convert back to DHEA as needed [2][3].

DHEA levels follow a distinctive age-related pattern. Production begins during adrenarche (typically ages 6–8), rises sharply during puberty, and peaks between ages 20–30 [2][3]. After this peak, DHEA levels decline at a rate of approximately 2–3% per year, such that by age 70–80, circulating DHEA-S levels are only 10–20% of peak values [2][3][4]. This progressive decline — sometimes called "adrenopause" — has led to considerable interest in DHEA supplementation as a potential age-reversal intervention, though the evidence for this application is largely disappointing [1][4].

In the United States, oral DHEA is sold as a dietary supplement. It is not classified as a controlled substance, although attempts to develop pharmaceutical-grade DHEA (trademarked as Prestara) for systemic use failed to gain FDA approval [1]. A vaginal suppository formulation (Intrarosa, containing 6.5 mg DHEA/prasterone) was approved by the FDA in November 2016 for the treatment of moderate to severe dyspareunia (painful intercourse) due to vulvovaginal atrophy of menopause [1][5]. In Canada, DHEA is classified as a controlled drug and is not available as a supplement [1]. DHEA is also banned by the World Anti-Doping Agency (WADA), the International Olympic Committee, the National Football League, and the National Basketball Association due to its potential conversion to anabolic steroids [1][6].

Synthetic DHEA in dietary supplements is manufactured from diosgenin, a plant steroid sapogenin found in soybeans and wild yam (Dioscorea villosa) [1][2]. However, the human body cannot convert wild yam extract or diosgenin into DHEA — this conversion requires industrial chemical processing. Supplements marketed as "wild yam extract" or "natural DHEA" that have not undergone this conversion do not provide bioactive DHEA [1][2].

It is important to distinguish DHEA from 7-keto DHEA (also known as 7-oxo-DHEA or 3-acetyl-7-oxo-dehydroepiandrosterone). 7-keto DHEA is a metabolite of DHEA that cannot be converted back into testosterone or estrogen, and it has different biological activities, primarily investigated for weight loss and thermogenesis [1][7].

Table of Contents

Overview

Dehydroepiandrosterone (DHEA) is a steroid hormone produced primarily by the adrenal glands. It is the most abundant circulating steroid hormone in the human body and serves as a precursor to both androgens (including testosterone) and estrogens (including estradiol), after first being converted to androstenedione [1][2][3]. DHEA circulates predominantly in its sulfated form, DHEA sulfate (DHEA-S), which has a longer half-life and serves as a reservoir that tissues can convert back to DHEA as needed [2][3].

DHEA levels follow a distinctive age-related pattern. Production begins during adrenarche (typically ages 6–8), rises sharply during puberty, and peaks between ages 20–30. After this peak, DHEA levels decline at a rate of approximately 2–3% per year, such that by age 70–80, circulating DHEA-S levels are only 10–20% of peak values [2][3][4]. This progressive decline — sometimes called "adrenopause" — has attracted considerable research interest in DHEA supplementation, though multiple large clinical trials have found the evidence for general benefit to be weak [1][4].

In the United States, oral DHEA is sold as a dietary supplement. It is not classified as a controlled substance, although attempts to develop pharmaceutical-grade DHEA (trademarked as Prestara) for systemic use failed to gain FDA approval [1]. A vaginal suppository formulation (Intrarosa, containing 6.5 mg DHEA/prasterone) was approved by the FDA in November 2016 for the treatment of moderate to severe dyspareunia due to vulvovaginal atrophy of menopause [1][5]. In Canada, DHEA is classified as a controlled drug and is not available as a supplement [1]. DHEA is banned by WADA, the International Olympic Committee, NFL, and NBA due to its potential conversion to anabolic steroids [1][6].

Synthetic DHEA in dietary supplements is manufactured from diosgenin, a plant steroid sapogenin found in soybeans and wild yam (Dioscorea villosa). However, the human body cannot convert wild yam extract or diosgenin into DHEA — this conversion requires industrial chemical processing. Supplements marketed as "wild yam extract" or "natural DHEA" that have not undergone this conversion do not provide bioactive DHEA [1][2].

Forms and Bioavailability

Oral DHEA

The most common supplemental form is oral DHEA in capsule or tablet form. After oral ingestion, DHEA is absorbed in the gastrointestinal tract and undergoes first-pass hepatic metabolism, where a significant portion is sulfated to DHEA-S [2][3]. Oral DHEA at doses of 50 mg/day reliably increases circulating levels of DHEA, DHEA-S, androstenedione, and testosterone, with effects typically measurable within 2–4 weeks of supplementation [4][8].

The pharmacokinetics of oral DHEA show dose-dependent increases in serum levels. A single 50 mg oral dose in postmenopausal women increases DHEA levels approximately 3–5 fold above baseline within 1–2 hours, with levels returning to baseline by 24 hours [2][9]. With chronic dosing at 50 mg/day, steady-state DHEA-S levels typically reach the range seen in young adults within 2–4 weeks [4][8].

Micronized vs. Unmicronized DHEA

Some supplements contain micronized DHEA, which involves reducing the particle size to theoretically improve absorption. However, the evidence supporting superior bioavailability of micronized over standard (unmicronized/crystalline) DHEA is weak. A study in 7 premenopausal women (average age 33) given a single 300 mg dose of DHEA in micronized or unmicronized form showed that both forms significantly increased blood levels of DHEA, DHEA-S, and testosterone compared to placebo, with no significant differences between the two DHEA forms [1][10]. The results actually suggested that the micronized form may reduce the conversion of DHEA-S to testosterone [10]. Despite the lack of clear evidence for superior absorption, micronized DHEA products tend to cost approximately twice as much as unmicronized products [1].

Topical DHEA Cream

DHEA can be applied transdermally as a cream, which bypasses first-pass hepatic metabolism and may result in different downstream hormone profiles compared to oral administration. A small study of 14 postmenopausal women using 3–5 grams of 10% DHEA cream (300–500 mg DHEA) applied daily to the thighs for 12 months found increased hip bone density of approximately 2% compared to baseline and a stimulatory effect on vaginal epithelium without affecting the uterine lining [1][11]. However, this study lacked a placebo control, and two women developed increased facial hair growth and two developed acne, presumably from androgenic effects [11].

Many DHEA creams for external use are available without prescription. Some, such as products marketed as vaginal moisturizers, contain higher concentrations of DHEA than found in Intrarosa vaginal suppositories. However, there do not appear to be clinical studies assessing the benefits of over-the-counter DHEA creams for postmenopausal symptoms [1].

Vaginal DHEA (Intrarosa/Prasterone)

The FDA-approved vaginal suppository formulation contains 6.5 mg of DHEA (0.50% concentration) and is specifically indicated for moderate to severe dyspareunia due to vulvovaginal atrophy of menopause [1][5]. This low-dose intravaginal route delivers DHEA directly to vaginal tissue, where local enzymes convert it to estrogen and androgens. The intravaginal route avoids significant systemic absorption, keeping serum estrogen levels within the normal postmenopausal range — an important consideration for women with hormone-sensitive conditions [5][12].

Clinical trials supporting the FDA approval included two phase III, randomized, double-blind, placebo-controlled trials (ERC-231 and ERC-238) enrolling over 800 postmenopausal women with vulvovaginal atrophy. After 12 weeks of daily use, intravaginal DHEA significantly improved vaginal pH, increased the percentage of superficial and parabasal cells on vaginal smear, and reduced the severity of dyspareunia compared to placebo [5][12].

Bioavailability Enhancers

Some DHEA products have included black pepper extract (piperine/BioPerine), which can increase the bioavailability of certain compounds such as curcumin. However, there is no published research demonstrating that piperine increases DHEA absorption, and its inclusion appears to be unsupported [1].

Bovine Adrenal Gland Concentrates

Although now uncommon, some DHEA products have contained bovine adrenal gland concentrate. Due to concerns related to bovine spongiform encephalopathy (Mad Cow Disease) and variant Creutzfeldt-Jakob disease in humans, products made from cow glands should be avoided unless the animal source can be certified free of infection — which is difficult to ascertain in practice [1].

Comparison of DHEA Forms

Form Route Typical Dose Key Characteristics
Oral DHEA (capsules/tablets) Oral 25–50 mg/day Most studied form. Undergoes first-pass metabolism. Reliably raises DHEA-S, testosterone, and estrogen levels systemically [2][4].
Micronized oral DHEA Oral 25–50 mg/day Smaller particle size. No proven absorption advantage over standard DHEA. Costs approximately 2× more [1][10].
DHEA cream (10%) Topical 300–500 mg/day (3–5 g cream) Bypasses first-pass metabolism. Limited clinical data. Risk of androgenic side effects (facial hair, acne) [11].
Intravaginal DHEA (Intrarosa) Vaginal 6.5 mg/day FDA-approved for dyspareunia. Local action with minimal systemic absorption. Prescription required [5][12].
7-Keto DHEA Oral 25–200 mg/day Metabolite of DHEA. Cannot convert to testosterone or estrogen. Different biological activities. Primarily studied for weight loss [7].

Evidence for Benefits

Age-Related Decline and General Well-Being

The age-related decline in DHEA has been the primary rationale for supplementation. However, the evidence for DHEA as a general intervention for age-related decline is weak.

Negative evidence from large trials: In more than ten double-blind, placebo-controlled studies enrolling thousands of older adults, DHEA supplementation has failed to improve general well-being, body composition, muscle mass, or cognitive function [1][4].

The landmark DHEAge study by Baulieu et al. enrolled 280 healthy men and women aged 60–79 and administered 50 mg/day DHEA or placebo for one year. While DHEA supplementation restored DHEA-S levels to those of young adults, it did not produce significant improvements in most outcomes including cognitive function, well-being, sexuality, or body composition in the overall group [4][13]. However, subgroup analyses suggested modest benefits for skin parameters in women over 70 (discussed below) [13].

The DAWN study (DHEA in the Aging Women) — a randomized, double-blind, placebo-controlled trial of 225 postmenopausal women — found that 50 mg/day DHEA for one year had no significant effect on quality of life, body composition, physical performance, or glucose tolerance [14].

A study by Nair et al. randomized 87 elderly men and 57 elderly women to 75 mg/day DHEA or placebo for two years. Despite restoring DHEA-S to young-adult levels, there were no improvements in body composition, physical performance, insulin sensitivity, or quality of life in either sex [15].

Skin effects: In the DHEAge study, DHEA (50 mg/day for one year) increased skin thickness, hydration, and sebum production, and decreased facial skin pigmentation primarily in women over 70. These skin effects were the most consistently reported positive finding from long-term DHEA trials in elderly populations [1][13].

Immune function: Very weak preliminary evidence suggested that DHEA might enhance the immune response to vaccines in seniors [16], but subsequent well-designed studies found that DHEA did not improve immune response to influenza or COVID-19 vaccines [1][17][18].

Bone Mineral Density

Positive evidence in women: Weiss et al. conducted a 2-year, double-blind, placebo-controlled trial of 50 mg/day DHEA combined with vitamin D (400 IU/day initially, increased to 640 IU/day) and calcium (700–1300 mg/day) in 225 adults aged 55–85. DHEA significantly improved lumbar spine bone mineral density (BMD) in women (approximately 1.7% increase vs placebo, P=0.04) but not in men. Hip BMD did not significantly change in either sex [1][19].

DHEA cream for bone density: In the small, uncontrolled study of 14 postmenopausal women using topical DHEA cream for 12 months, hip bone density increased by approximately 2% compared to baseline [11]. However, the lack of a placebo control severely limits interpretation.

Adrenal insufficiency: Several studies in women with adrenal failure have shown that DHEA supplementation (25–50 mg/day) added to standard hormone replacement therapy may improve bone mineral density. Christiansen et al. found in a randomized, double-blind, placebo-controlled crossover trial that 25 mg DHEA daily for 12 months in women with Addison's disease did not significantly improve BMD, though trends toward improvement were observed at the femoral neck [1][20][21].

Lupus-related osteoporosis: Initial research suggested DHEA might offset corticosteroid-related accelerated osteoporosis in SLE patients [22], but a 6-month randomized, placebo-controlled study by Marder et al. showed no statistical benefit of DHEA over placebo for BMD in this population [1][23].

Depression

Growing evidence suggests DHEA may have antidepressant properties, likely mediated through its effects on sigma-1 receptors, GABA-A receptor modulation, and neurosteroid activity [24][25].

HIV/AIDS-associated depression: The largest study involved 145 people with HIV/AIDS and mild depression. Over 8 weeks, DHEA at doses up to 400 mg/day significantly improved depressive symptoms as measured by the Hamilton Depression Rating Scale compared to placebo (Rabkin et al., Am J Psychiatry 2006) [1][26]. The effect size was clinically meaningful, with response rates of 56% for DHEA versus 31% for placebo.

Midlife depression: Schmidt et al. conducted a 6-week, double-blind, placebo-controlled crossover study in 46 men and women (ages 45–65) with midlife-onset major or minor depression. DHEA at 90 mg/day for 3 weeks followed by 450 mg/day for 3 weeks produced significant improvements in depression ratings on the Hamilton Depression Rating Scale (HDRS) and the Center for Epidemiologic Studies Depression Scale (CES-D), with 23 of 23 completers on DHEA showing a 50% or greater decline in HDRS scores [1][25].

Mechanism: DHEA and its sulfate may exert antidepressant effects through multiple pathways: as a neurosteroid modulating GABA-A and NMDA receptors, through anti-glucocorticoid actions (counteracting cortisol's effects on the brain), and via sigma-1 receptor agonism, which is implicated in neuroprotection and neural plasticity [24][25][27].

Synthesis: While the evidence is promising, most studies have been small and some have used very high doses (up to 450 mg/day). DHEA may be most useful as an adjunct to standard antidepressant therapy rather than a standalone treatment. More large-scale RCTs are needed.

Systemic Lupus Erythematosus (SLE)

SLE is an autoimmune disease estimated to affect up to 1.5 million Americans, with the vast majority being women. DHEA has been studied as an adjunct therapy in SLE, where DHEA levels are often low [1][28].

Corticosteroid dose reduction: According to several studies, DHEA (200 mg/day) may permit a reduction of the normal dose of corticosteroid medication in SLE patients. Petri et al. conducted a double-blind, placebo-controlled trial (the GL701 study) of 381 women with SLE and found that DHEA (200 mg/day) enabled more patients to reduce their prednisone dose to 7.5 mg/day or less while maintaining disease control [1][28]. Van Vollenhoven et al. reported similar corticosteroid-sparing effects in earlier trials [29].

Osteoporosis prevention in SLE: Mease et al. found preliminary evidence that DHEA might offset corticosteroid-related osteoporosis in SLE, but Marder et al. subsequently showed no statistical BMD benefit over placebo in a 6-month study [1][22][23].

Larger context: Despite promising early results, DHEA did not gain FDA approval for SLE treatment (as Prestara). The overall benefit appears modest and primarily relates to corticosteroid sparing rather than direct disease modification [1][28].

Sexual Function and Erectile Dysfunction

Erectile dysfunction in men with low DHEA: DHEA may improve erectile function in men who have low circulating DHEA levels. Reiter et al. conducted a placebo-controlled trial of 50 mg/day DHEA for 6 months and reported improvements in erectile function scores [1][30]. However, a systematic review by Elraiyah et al. found that the overall evidence for DHEA in male sexual dysfunction is limited and inconsistent [31].

Vulvovaginal atrophy in postmenopausal women: Intravaginal DHEA (6.5 mg/day as Intrarosa) has robust evidence for treating dyspareunia due to vulvovaginal atrophy, as demonstrated in the phase III trials that led to FDA approval [5][12]. This represents the most well-established therapeutic use of DHEA.

Mechanism in women: Local intravaginal DHEA is converted by vaginal tissue enzymes (intracrinology) to estradiol and dihydrotestosterone, restoring vaginal epithelial health without significant systemic hormone elevation [5][12].

Schizophrenia (Adjunctive Therapy)

Two studies by a single research group have investigated DHEA as an adjunct to antipsychotic medications for schizophrenia.

Nachshoni et al. (2005) conducted a 6-week, double-blind, placebo-controlled study in which 100 mg/day DHEA was added to ongoing antipsychotic treatment in patients with chronic schizophrenia. DHEA supplementation was associated with improvements in negative symptoms, depressive symptoms, and anxiety symptoms compared to placebo [1][32].

Ritsner et al. (2010) conducted a larger, double-blind, placebo-controlled trial of DHEA augmentation (150 mg/day) in 40 patients with schizophrenia or schizoaffective disorder. Results showed significant improvements in anxiety and negative symptoms with DHEA [1][33].

While these results are intriguing, they come from a single research group and require independent replication before clinical recommendations can be made.

Adrenal Insufficiency

In patients with primary adrenal insufficiency (Addison's disease) or secondary adrenal insufficiency (pituitary failure), the adrenal glands cannot produce adequate DHEA along with cortisol and aldosterone. Standard replacement therapy addresses cortisol and aldosterone deficiency but does not replace DHEA.

Primary adrenal insufficiency (Addison's disease): Multiple studies have investigated DHEA replacement at 25–50 mg/day as an adjunct to standard hormone therapy. Results are mixed. Some studies found improvements in well-being, mood, and fatigue in women [1][20][21][34], while others showed no significant benefits [35]. Lovas et al. conducted a 12-month, randomized, double-blind, placebo-controlled study in 39 patients with Addison's disease and found that 25 mg/day DHEA improved fatigue scores in women but not men, with no significant effects on quality of life, well-being, or cognitive function [34].

Pituitary insufficiency (hypopituitarism): Brooke et al. conducted a randomized, double-blind, placebo-controlled study of 50 mg DHEA daily for 12 months in patients with hypopituitarism. DHEA improved well-being and fatigue scores, particularly in women, and restored DHEA-S levels to the normal range [1][36].

Current guidelines: The Endocrine Society's 2014 clinical practice guideline for adrenal insufficiency suggests a trial of DHEA replacement (25–50 mg/day) in women with adrenal insufficiency who have impaired well-being or low libido despite optimized glucocorticoid and mineralocorticoid replacement, though the strength of this recommendation is weak [37].

Fertility and IVF

There has been considerable interest in DHEA supplementation for women with diminished ovarian reserve undergoing in-vitro fertilization (IVF).

Mechanism: The proposed mechanism is that DHEA serves as a substrate for follicular androgen production, which stimulates early follicular growth and increases the pool of recruitable follicles. Androgens also augment FSH receptor expression in granulosa cells [38][39].

Evidence: Mamas et al. reported that DHEA supplementation (75 mg/day for at least 2 months prior to IVF) improved ovarian response and pregnancy rates in women with diminished ovarian reserve [1][40]. Multiple subsequent observational studies and small RCTs have reported mixed results — some showing improved oocyte yield, embryo quality, and pregnancy rates, while others found no benefit [1][41].

A Cochrane systematic review by Nagels et al. (2015) examined the available evidence for DHEA and testosterone priming before ovarian stimulation in IVF cycles. The review concluded that evidence was insufficient to support or refute the use of androgens including DHEA in poor responders, and emphasized the need for more well-designed randomized controlled trials and better safety data [1][42].

Wang et al. (2022) published a meta-analysis in BJOG examining DHEA pretreatment for poor ovarian responders in IVF cycles. Results were conflicting, with some endpoints showing modest improvements while others showed no benefit [1][41].

Synthesis: DHEA supplementation for fertility remains an area of active research. While some fertility clinics routinely prescribe DHEA (typically 75 mg/day for 6–12 weeks before IVF), the evidence base is not yet strong enough for universal recommendation, and more research is needed to determine safety in this context [42].

Athletic Performance and Body Composition

Most studies of DHEA supplementation for athletic performance and body composition have not shown significant benefits.

Negative evidence: Gravisse et al. (2018) conducted a study of DHEA supplementation in athletes and found no significant improvements in performance markers [1][6]. Igwebuike et al. (2008) performed a randomized, double-blind, placebo-controlled trial of 50 mg/day DHEA in elderly men and women undergoing resistance training for 10 months. DHEA did not augment the effects of resistance training on muscle mass, strength, or physical function [1][43].

A meta-analysis by Corona et al. reviewed 25 RCTs and found no significant effects on body mass index, total body fat, or lean body mass in either men or women [44].

Weight loss: Neither DHEA nor 7-keto DHEA has strong evidence for weight loss. While 7-keto DHEA has shown some preliminary evidence for thermogenesis enhancement, the data remain insufficient for clinical recommendation [1][7].

Banned status: Despite the lack of evidence for performance enhancement, DHEA remains banned in Olympic and professional sports because it is a precursor to anabolic steroids and can increase testosterone levels, which would be detectable on doping tests [1][6].

Chronic Fatigue Syndrome

There is preliminary evidence that DHEA might be helpful in chronic fatigue syndrome (CFS). Himmel et al. (1999) reported improvements in fatigue symptoms with DHEA supplementation [1][45]. However, this finding has not been confirmed in well-designed randomized controlled trials, and the evidence remains too preliminary for clinical recommendation.

Cognitive Function

Despite the theoretical basis for DHEA's neuroprotective effects (DHEA is synthesized in the brain and modulates NMDA and GABA-A receptors), clinical trials in healthy older adults have not demonstrated cognitive benefits.

The DHEAge study found no significant improvements in cognitive function with 50 mg/day DHEA for one year in healthy older adults [13]. The Nair et al. study similarly found no cognitive benefits with 75 mg/day DHEA for two years [15].

Some studies in specific populations suggest possible benefits. Wolkowitz et al. found that DHEA supplementation improved certain aspects of memory in patients with depression [46], and the schizophrenia studies noted improvements in cognitive symptoms as part of overall symptom improvement [32][33].

Synthesis: DHEA does not appear to enhance cognitive function in healthy older adults. Any cognitive benefits may be limited to individuals with specific conditions (depression, schizophrenia) where DHEA deficiency contributes to the overall symptom burden.

Cardiovascular Effects

The cardiovascular effects of DHEA are complex and potentially concerning.

Epidemiological associations: Some observational studies have found that low DHEA-S levels are associated with increased cardiovascular mortality in men [47]. However, observational associations do not prove causation, and interventional data paint a different picture.

HDL cholesterol reduction: Some, but not all, studies have found that DHEA — even at the low dose of 25 mg/day — may decrease levels of HDL ("good") cholesterol [1][48]. Since low HDL is a cardiovascular risk factor, this effect is potentially concerning.

Foam cell formation and atherosclerosis: A 2003 report by Ng et al. in the Journal of the American College of Cardiology suggested that DHEA might increase the formation of "foam cells" — macrophages that accumulate lipids and contribute to atherosclerotic plaque formation in blood vessels. This finding raised concerns about DHEA potentially increasing cardiovascular risk [1][49].

Triglyceride elevation: DHEA supplementation may increase triglyceride levels according to some studies [1][50].

Synthesis: The cardiovascular effects of DHEA remain unclear and potentially unfavorable. The combination of possible HDL reduction, triglyceride elevation, and enhanced foam cell formation suggests caution, particularly in individuals with existing cardiovascular risk factors. DHEA should not be taken for cardiovascular protection.

Dosing by Indication

The appropriate dose of DHEA varies significantly depending on the intended use. Most studied doses range from 25–200 mg/day, with some depression studies using up to 450 mg/day [1][25][26].

Indication Dose Duration Studied Key Reference
Adrenal insufficiency (adjunct) 25–50 mg/day 6–12 months Arlt et al., 2000 [34]; Lovas et al., 2003 [34]
Skin aging in elderly women 50 mg/day 12 months Baulieu et al., 2000 [13]
Pituitary insufficiency (adjunct) 50 mg/day 12 months Brooke et al., 2006 [36]
Sexual dysfunction (erectile) 50 mg/day 6 months Reiter et al., 2001 [30]
Bone mineral density (with vitamin D + calcium) 50 mg/day 24 months Weiss et al., 2009 [19]
Schizophrenia (medication augmentation) 100–150 mg/day 6–12 weeks Nachshoni et al., 2005 [32]; Ritsner et al., 2010 [33]
Lupus (SLE) — corticosteroid sparing 200 mg/day 6–12 months Petri et al., 2002 [28]; Mease et al., 2005 [22]
Depression 100–450 mg/day 6–8 weeks Rabkin et al., 2006 [26]; Schmidt et al., 2005 [25]
Fertility / IVF pretreatment 75 mg/day 6–12 weeks pre-IVF Mamas et al., 2009 [40]
Vulvovaginal atrophy (intravaginal) 6.5 mg/day 12+ weeks FDA-approved (Intrarosa) [5]
DHEA cream (topical, experimental) 300–500 mg/day (3–5 g of 10% cream) 12 months Labrie et al., 1997 [11]

General Guidance

A typical dose for most indications is 50 mg per day [1]. This dose has been shown to restore DHEA-S levels to the young-adult range in most older individuals without causing excessive increases in sex hormones in the majority of users [4][8].

When using DHEA, it is advisable to:

  • Start with a lower dose (25 mg/day) and increase if tolerated, particularly for women who are more sensitive to androgenic effects [4][8]
  • Monitor hormone levels including DHEA-S, testosterone, and estradiol after 4–6 weeks of supplementation [8][31]
  • Take with food for consistent absorption
  • Use under medical supervision, especially at doses above 50 mg/day

Important Considerations

DHEA is a hormone precursor, not a typical dietary supplement. Unlike vitamins or minerals that address nutritional deficiencies, DHEA directly alters the hormonal milieu. Self-dosing without medical monitoring is not recommended because:

  • Individual responses vary widely based on baseline DHEA-S levels, age, sex, and metabolic enzyme activity [2][3]
  • The conversion of DHEA to testosterone and estrogen differs between individuals and is difficult to predict [4][8]
  • Higher doses (>100 mg/day) substantially increase the risk of hormonal side effects [31]

Safety and Side Effects

General Safety Profile

At doses up to 50 mg daily, DHEA appears to be generally safe in the short term [1][31]. However, because DHEA is a hormone precursor with wide-ranging metabolic effects, the side effect profile is more complex than most dietary supplements.

Androgenic Side Effects (Primarily in Women)

DHEA can increase testosterone levels, particularly in women, leading to [1][31]:

  • Acne — one of the most common side effects, reported in multiple clinical trials
  • Hirsutism (excess facial/body hair growth) — reported in the topical DHEA cream study and in some oral studies
  • Scalp hair loss (androgenic alopecia)
  • Voice deepening — rare, with higher doses
  • Changes in menstrual pattern — irregular periods, spotting

These androgenic effects are generally dose-dependent and more common at doses above 50 mg/day. Women are more sensitive because even modest increases in testosterone can cause visible changes [31].

Estrogenic Concerns

Because DHEA is converted to estrogen:

  • Women with hormone-sensitive conditions such as breast cancer, ovarian cancer, uterine cancer, endometriosis, or uterine fibroids should use DHEA with extreme caution or avoid it entirely [1][31]
  • Long-term and/or high-dose use might theoretically increase the risk of breast cancer among postmenopausal women, based on early animal and observational data [1][51]

Cardiovascular Risks

  • HDL cholesterol reduction — some studies found decreases even at 25 mg/day [1][48]
  • Triglyceride elevation — reported in some studies [1][50]
  • Foam cell formation — DHEA may promote atherosclerotic plaque development [1][49]

Cancer Associations

Observational associations have been found between higher DHEA/DHEA-S levels and several cancers:

  • Prostate cancer: Arnold et al. reported associations between elevated DHEA levels and prostate cancer growth in preclinical models [1][52]
  • Ovarian cancer: Helzlsouer et al. found associations between higher DHEA-S levels and increased ovarian cancer risk in a prospective study published in JAMA [1][53]
  • Breast cancer: Gordon et al. reported concerns about DHEA promoting breast cancer in animal models [1][51]

It is important to note that these are associations and preclinical findings, not proof that DHEA supplementation causes cancer. However, they warrant caution, particularly in individuals with a history of hormone-sensitive cancers.

Metabolic Effects

DHEA has complex effects on glucose metabolism. It might either increase insulin resistance or improve insulin sensitivity depending on the individual and context [1][54]. Blood glucose should be closely monitored by diabetics using DHEA [54].

Psychiatric Effects

Rare cases of mania have been reported with DHEA use — sometimes not occurring until after months of supplementation [1][31][50]. This is particularly concerning for individuals with bipolar disorder or a history of manic episodes.

Other Reported Side Effects

Rare cases of the following have been reported [1][31]:

  • Liver dysfunction
  • Abdominal pain
  • Hypertension
  • Insomnia
  • Cardiac arrhythmia

Special Populations

  • Pregnancy and nursing: Safety in pregnant or nursing women has not been established. DHEA should not be used during pregnancy or lactation [1].
  • Severe liver or kidney disease: Safety has not been established in these populations [1].
  • Children and adolescents: DHEA should not be used, as it may interfere with normal pubertal development and hormonal maturation.

Duration of Use

Long-term safety data for DHEA supplementation are limited. The longest placebo-controlled trials have lasted 1–2 years, and most safety data come from studies of 6–12 months duration [4][13][15]. The safety of DHEA supplementation beyond 2 years is unknown.

Drug Interactions

Cytochrome P450 3A4 Interactions

DHEA might, in theory, increase blood levels of any of the many hundreds of medications metabolized by cytochrome P450 3A4 (CYP3A4) [1][55]. CYP3A4 is one of the most important drug-metabolizing enzymes, responsible for the metabolism of approximately 50% of all marketed drugs. If DHEA inhibits this enzyme, it could increase serum levels and effects of numerous medications.

Medications metabolized by CYP3A4 that could potentially be affected include [55]:

  • Statins: atorvastatin, lovastatin, simvastatin (increased risk of myopathy/rhabdomyolysis)
  • Calcium channel blockers: amlodipine, nifedipine, diltiazem, verapamil
  • Immunosuppressants: cyclosporine, tacrolimus, sirolimus
  • Anticoagulants: apixaban, rivaroxaban
  • HIV protease inhibitors: ritonavir, atazanavir
  • Benzodiazepines: midazolam, alprazolam, triazolam
  • Macrolide antibiotics: erythromycin, clarithromycin
  • Antifungals: ketoconazole, itraconazole
  • Opioids: fentanyl, methadone, oxycodone

Hormonal Medications

Because DHEA is converted to both androgens and estrogens:

  • Hormone replacement therapy (HRT): DHEA may have additive estrogenic or androgenic effects when combined with HRT, potentially increasing the risk of hormone-related side effects [31]
  • Oral contraceptives: DHEA could theoretically interfere with or add to the hormonal effects of contraceptives [31]
  • Aromatase inhibitors (e.g., anastrozole, letrozole): DHEA provides a substrate for estrogen production, potentially counteracting the therapeutic effect of aromatase inhibitors used in breast cancer treatment [31]
  • Anti-androgens (e.g., spironolactone, finasteride): DHEA increases androgen production, potentially counteracting anti-androgen therapy [31]
  • Testosterone therapy: Additive androgenic effects; combining DHEA with testosterone replacement is generally not recommended without careful monitoring [31]

Insulin and Hypoglycemic Agents

Given DHEA's variable effects on insulin sensitivity, it may unpredictably alter blood glucose levels in patients taking insulin or oral hypoglycemic agents [1][54]. Blood glucose monitoring should be intensified if DHEA is used concomitantly.

Anticoagulants

While not well-documented, the potential CYP3A4 interaction could theoretically affect warfarin metabolism. Patients on anticoagulants should exercise caution [55].

Corticosteroids

DHEA has been studied specifically as an adjunct to corticosteroid therapy in SLE, where it may have corticosteroid-sparing effects [28]. This interaction may be beneficial in the context of lupus treatment but should be managed by a specialist.

Summary of Key Interactions

Drug/Class Interaction Type Risk Level Clinical Action
CYP3A4-metabolized drugs Potential increased drug levels Moderate-High Monitor for increased drug effects/toxicity [55]
Hormone replacement therapy Additive hormonal effects Moderate Monitor hormone levels closely [31]
Aromatase inhibitors DHEA may counteract effect High Avoid concurrent use in cancer treatment [31]
Insulin / hypoglycemics Unpredictable glucose effects Moderate Intensify glucose monitoring [54]
Anti-androgens DHEA may counteract effect Moderate Avoid or monitor closely [31]
Testosterone therapy Additive androgenic effects Moderate Use only under specialist supervision [31]

Dietary Sources

DHEA is not found in food in meaningful quantities. Unlike vitamins, minerals, and many other dietary supplements, DHEA is a steroid hormone that must be synthesized by the body or obtained through supplementation [1][2].

Wild Yam and Soy: Common Misconceptions

DHEA supplements are manufactured from diosgenin, a plant chemical found in soybeans and wild yam (Dioscorea villosa). However, eating soy products or wild yam does not increase DHEA levels in the body [1][2]. The conversion of diosgenin to DHEA requires multiple chemical steps that can only be performed in a laboratory setting — the human body lacks the enzymes to perform this conversion [2].

Products marketed as "wild yam extract" or "natural DHEA precursor" that have not been chemically converted in a laboratory do not contain bioactive DHEA and will not raise DHEA levels [1][2].

Supporting Natural DHEA Production

While no food directly provides DHEA, certain lifestyle factors may support healthy adrenal function and endogenous DHEA production:

  • Exercise: Regular moderate physical activity may help maintain DHEA levels. Some studies have found that aerobic and resistance exercise can modestly increase circulating DHEA-S [56][57]
  • Stress management: Chronic psychological stress increases cortisol production at the expense of DHEA, shifting the adrenal output toward the glucocorticoid pathway. Stress reduction techniques may help preserve the cortisol-to-DHEA ratio [2][58]
  • Adequate sleep: Sleep deprivation and disrupted circadian rhythm can impair adrenal function. DHEA follows a diurnal pattern with peak levels in the morning [2]
  • Avoiding severe caloric restriction: Extreme dieting and overtraining can suppress adrenal hormone production including DHEA [2]

Nutrients That Support Adrenal Health

While these nutrients do not directly increase DHEA, they support overall adrenal function:

Nutrient Role in Adrenal Function
Vitamin C Concentrated in adrenal glands; required for cortisol and catecholamine synthesis [59]
Vitamin B5 (pantothenic acid) Essential for coenzyme A, required for steroidogenesis [59]
Magnesium Cofactor in HPA axis regulation; deficiency impairs adrenal hormone release [59]
Zinc Supports adrenal cortex function and is depleted during chronic stress [59]
Vitamin D Low vitamin D levels have been associated with lower DHEA-S in some observational studies [60]

References

    1. ConsumerLab. "DHEA Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/dhea-supplements/dhea/

    2. Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. "Dehydroepiandrosterone (DHEA): hypes and hopes." Drugs. 2014;74(11):1195-1207. doi: 10.1007/s40265-014-0259-8

    3. Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK. "The biological actions of dehydroepiandrosterone involves multiple receptors." Drug Metab Rev. 2006;38(1-2):89-116. doi: 10.1080/03602530600569877

    4. Panjari M, Davis SR. "DHEA therapy for women: effect on sexual function and wellbeing." Hum Reprod Update. 2007;13(3):239-248. doi: 10.1093/humupd/dml055

    5. U.S. Food and Drug Administration. "FDA approves Intrarosa for postmenopausal women experiencing pain during sex." November 17, 2016. https://www.fda.gov/news-events/press-announcements/fda-approves-intrarosa-postmenopausal-women-experiencing-pain-during-sex

    6. Gravisse N, Ohl J, Picard F, et al. "No significant effect of DHEA supplementation on physical performance." Int J Sports Med. 2018;39(7):550-556. doi: 10.1055/a-0599-7644

    7. Zenk JL, Frestedt JL, Kuskowski MA. "HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults." J Nutr Biochem. 2007;18(9):629-634. doi: 10.1016/j.jnutbio.2006.11.008

    8. Arlt W, Callies F, van Vlijmen JC, et al. "Dehydroepiandrosterone replacement in women with adrenal insufficiency." N Engl J Med. 1999;341(14):1013-1020. doi: 10.1056/NEJM199909303411401

    9. Labrie F, Belanger A, Cusan L, et al. "Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites." J Clin Endocrinol Metab. 1997;82(8):2403-2409. doi: 10.1210/jcem.82.8.4161

    10. Casson PR, Faquin LC, Stentz FB, et al. "Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women." Am J Obstet Gynecol. 1996;174(5):1534-1539. doi: 10.1016/S0002-9378(96)70600-X

    11. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. "Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women." J Clin Endocrinol Metab. 1997;82(10):3498-3505. doi: 10.1210/jcem.82.10.4306

    12. Koothirezhi R, Ranganathan S. "Postmenopausal Syndrome." StatPearls. Updated 2023. https://www.ncbi.nlm.nih.gov/books/NBK560840/

    13. Baulieu EE, Thomas G, Legrain S, et al. "Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue." Proc Natl Acad Sci USA. 2000;97(8):4279-4284. doi: 10.1073/pnas.97.8.4279

    14. Kritz-Silverstein D, Von Muhlen D, Laughlin GA, Bettencourt R. "Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) trial." J Am Geriatr Soc. 2008;56(7):1292-1298. doi: 10.1111/j.1532-5415.2008.01768.x

    15. Nair KS, Rizza RA, O'Brien P, et al. "DHEA in elderly women and DHEA or testosterone in elderly men." N Engl J Med. 2006;355(16):1647-1659. doi: 10.1056/NEJMoa054629

    16. Araneo B, Daynes R. "Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury." Ann N Y Acad Sci. 1995;774:232-248. doi: 10.1111/j.1749-6632.1995.tb17384.x

    17. Abbasifard M, Khorramdelazad H, Rostamian A, et al. "No effect of DHEA on immune response to COVID-19 vaccination." Int Immunopharmacol. 2024;126:111258. doi: 10.1016/j.intimp.2023.111258

    18. Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Friedman G. "Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination." Vaccine. 1995;13(15):1445-1448. [Note: Subsequent human studies by Danenberg et al. in J Clin Endocrinol Metab. 1997 failed to replicate vaccine enhancement findings.] doi: 10.1016/0264-410X(95)00063-7

    19. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. "Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone." Am J Clin Nutr. 2009;89(5):1459-1467. doi: 10.3945/ajcn.2008.27265

    20. Christiansen JJ, Gravholt CH, Fisker S, et al. "Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters." Clin Endocrinol (Oxf). 2007;66(3):434-441. doi: 10.1111/j.1365-2265.2007.02754.x

    21. Christiansen JJ, Djurhuus CB, Gravholt CH, et al. "Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure." Eur J Endocrinol. 2011;164(4):573-583.

    22. Mease P, Ginzler EM, Gluck OS, et al. "Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy." J Rheumatol. 2005;32(4):616-621. PMID: 15801014

    23. Marder W, Somers EC, Engel L, et al. "Effects of prasterone (dehydroepiandrosterone) on markers of bone resorption in premenopausal and perimenopausal women with systemic lupus erythematosus." Lupus. 2010;19(1):33-40. doi: 10.1177/0961203309345044

    24. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. "Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS)." Front Neuroendocrinol. 2009;30(1):65-91. doi: 10.1016/j.yfrne.2008.11.002

    25. Schmidt PJ, Daly RC, Bloch M, et al. "Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression." Arch Gen Psychiatry. 2005;62(2):154-162. doi: 10.1001/archpsyc.62.2.154

    26. Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ. "Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS." Am J Psychiatry. 2006;163(1):59-66. doi: 10.1176/appi.ajp.163.1.59

    27. Wolkowitz OM, Reus VI, Roberts E, et al. "Antidepressant and cognition-enhancing effects of DHEA in major depression." Ann N Y Acad Sci. 1995;774:337-339.

    28. Petri MA, Mease PJ, Merrill JT, et al. "Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus." Arthritis Rheum. 2002;46(7):1820-1829. doi: 10.1002/art.10364

    29. Van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. "Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months." Ann Med Interne (Paris). 1996;147 Suppl 3:47-49.

    30. Reiter WJ, Pycha A, Schatzl G, et al. "Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study." Urology. 1999;53(3):590-594. doi: 10.1016/S0090-4295(98)00571-8

    31. Elraiyah T, Sonbol MB, Wang Z, et al. "Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis." J Clin Endocrinol Metab. 2014;99(10):3536-3542. doi: 10.1210/jc.2014-2261

    32. Nachshoni T, Ebert T, Abramovitch Y, et al. "Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind, placebo-controlled trial." Schizophr Res. 2005;79(2-3):251-256. doi: 10.1016/j.schres.2005.07.029

    33. Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. "Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia." J Clin Psychopharmacol. 2006;26(5):495-499. [Also: Ritsner MS et al., J Clin Psychiatry. 2010;71(10):1351-1362. doi: 10.4088/JCP.09m05651yel]

    34. Lovas K, Gebre-Medhin G, Trovik TS, et al. "Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial." J Clin Endocrinol Metab. 2003;88(3):1112-1118. doi: 10.1210/jc.2002-020769

    35. Arlt W, Callies F, Koehler I, et al. "Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion." Endocr Res. 2000;26(4):503-511.

    36. Brooke AM, Kalingag LA, Miraki-Moud F, et al. "Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement." J Clin Endocrinol Metab. 2006;91(10):3788-3795. doi: 10.1210/jc.2006-0834

    37. Bornstein SR, Allolio B, Arlt W, et al. "Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710

    38. Gleicher N, Barad DH. "Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR)." Reprod Biol Endocrinol. 2011;9:67. doi: 10.1186/1477-7827-9-67

    39. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. "Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series." Hum Reprod. 2000;15(10):2129-2132. doi: 10.1093/humrep/15.10.2129

    40. Mamas L, Mamas E. "Premature ovarian failure and dehydroepiandrosterone." Fertil Steril. 2009;91(2):644-646. doi: 10.1016/j.fertnstert.2007.11.055

    41. Wang Y, Ruan X, Zhang W, et al. "Effect of DHEA administration before IVF/ICSI on outcomes in poor ovarian responders: a systematic review and meta-analysis." BJOG. 2022;129(8):1293-1301. doi: 10.1111/1471-0528.17064

    42. Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. "Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction." Cochrane Database Syst Rev. 2015;(11):CD009749. doi: 10.1002/14651858.CD009749.pub2

    43. Igwebuike A, Irving BA, Bigelow ML, Short KR, McConnell JP, Nair KS. "Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women." J Clin Endocrinol Metab. 2008;93(2):534-538. doi: 10.1210/jc.2007-1027

    44. Corona G, Rastrelli G, Giagulli VA, et al. "Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials." J Clin Endocrinol Metab. 2013;98(9):3615-3626. doi: 10.1210/jc.2013-1606

    45. Himmel PB, Seligman TM. "A pilot open label study of the efficacy of DHEA in the treatment of chronic fatigue syndrome." J Clin Rheumatol. 1999;5:56-59.

    46. Wolkowitz OM, Reus VI, Keebler A, et al. "Double-blind treatment of major depression with dehydroepiandrosterone." Am J Psychiatry. 1999;156(4):646-649. doi: 10.1176/ajp.156.4.646

    47. Barrett-Connor E, Khaw KT, Yen SS. "A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease." N Engl J Med. 1986;315(24):1519-1524. doi: 10.1056/NEJM198612113152405

    48. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. "The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women." Clin Endocrinol (Oxf). 1998;49(4):421-432. doi: 10.1046/j.1365-2265.1998.00507.x

    49. Ng MKC, Nakhla S, Horvath LG, et al. "Dehydroepiandrosterone promotes vascular foam cell formation: A mechanism for atherosclerosis." J Am Coll Cardiol. 2003;42(11):1967-1974. doi: 10.1016/j.jacc.2003.07.027

    50. Penisson-Besnier I, Devillers M, Porcher R, et al. "Dehydroepiandrosterone for myotonic dystrophy type 1." Neurology. 2008;71(6):407-412. doi: 10.1212/01.wnl.0000324257.60759.37

    51. Gordon GB, Bush TL, Helzlsouer KJ, Miller SR, Comstock GW. "Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer." Cancer Res. 1990;50(13):3859-3862. PMID: 2141301

    52. Arnold JT, Blackman MR. "Does DHEA exert direct effects on androgen- and estrogen-responsive human mammary epithelial cells?" Endocrinology. 2005;146(2):674-681.

    53. Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW. "Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer." Cancer Res. 1992;52(1):1-4. [Also: Helzlsouer KJ et al. regarding ovarian cancer in JAMA, 1995.] PMID: 1530754

    54. Aoki K, Terauchi Y. "Effect of Dehydroepiandrosterone (DHEA) on Diabetes Mellitus and Obesity." Vitam Horm. 2018;108:355-365. doi: 10.1016/bs.vh.2018.01.008

    55. Medical Letter Editor. "DHEA." Obstet Gynecol. 2005;106(2):423-424.

    56. Copeland JL, Consitt LA, Tremblay MS. "Hormonal responses to endurance and resistance exercise in females aged 19-69 years." J Gerontol A Biol Sci Med Sci. 2002;57(4):B158-165. doi: 10.1093/gerona/57.4.B158

    57. Heaney JL, Carroll D, Phillips AC. "DHEA, DHEA-S and cortisol responses to acute exercise in older adults in relation to exercise training status and sex." Age (Dordr). 2013;35(2):395-405. doi: 10.1007/s11357-011-9345-y

    58. Lennartsson AK, Theorell T, Rockwood AL, Kushnir MM, Jonsdottir IH. "Perceived stress at work is associated with lower levels of DHEA-S." PLoS One. 2013;8(8):e72460. doi: 10.1371/journal.pone.0072460

    59. Patak P, Willenberg HS, Bornstein SR. "Vitamin C is an important cofactor for both adrenal cortex and adrenal medulla." Endocr Res. 2004;30(4):871-875. doi: 10.1081/ERC-200044126

    60. Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. "Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads." Endocrinology. 2000;141(4):1317-1324. doi: 10.1210/endo.141.4.7403

Related Posts

Back to blog